Meng-Ju Wu, PhD
Research Focus - Oncometabolites and Immune Evasion in Liver and Other Solid Cancers
- Understanding how metabolic and epigenetic alterations, such as mutant IDH1 and other frequent liver cancer mutations, reprogram tumor–immune interactions
- Defining how oncometabolites like 2-hydroxyglutarate suppress innate and adaptive immune sensing and create therapeutic vulnerabilities
- Investigating tumor-intrinsic and immune-intrinsic mechanisms using mouse models, human and patient-derived primary cancer cell lines, and PBMC-derived immune cells
- Identifying metabolic and chromatin regulators that drive immune evasion through CRISPR screening, multi-omics profiling, and single-cell approaches
- Translating mechanistic insights into combination therapies that enhance anti-tumor immunity in cholangiocarcinoma and other solid cancers
Representative Publication
Wu MJ, Kondo H, Kammula AV, et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024;385(6705):eadl6173.